Champions Oncology Inc.

Last updated September 27, 2026

Organization details

Legal name
Champions Oncology Inc.
Former names
Champions Biotechnology, INC. Champions Sports Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Baltimore
Headquarters state / province
Maryland
Headquarters country
United States
Fiscal year end
April
Ticker symbol
CSBR
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000771856
EIN
52-1401755
Wikidata ID
Q16829203

Board of directors

Chief executives

Since June 2021
74 CEO score

Strong · grade B

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%
74

7.7% a year in revenue

20% of the scoring weight is on file. Figures cover April 2021 – April 2026.

Ronnie Morris · CEO
Until June 2021 · Former

Director election results

Annual meeting of October 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

2 of this board's directors also sit on 3 other boards. 2 are in the same sector.

Network of Champions Oncology Inc.'s board connections Ascentage Pharma Group International Ascentage Pharma Group... Eocene Ltd. Eocene Ltd. Kodiak AI Inc. Kodiak AI Inc. David Sidransky David Sidransky Scott R. Tobin Scott R. Tobin Champions Oncology Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Oct 15, 2026 Joel Ackerman Director Option exercise +69,794 $1.60 $111,670
Oct 30, 2025 Joel Ackerman Director Option exercise +94,405 $2.10 $198,251
Mar 25, 2025 Philip P. Breitfeld Director Other −4,150 — —
Oct 31, 2024 Joel Ackerman Director Option exercise +88,470 $2.10 $185,787
Oct 31, 2024 Joel Ackerman Director Option exercise +16,667 $5.43 $90,502
Jan 12, 2024 Daniel Newman Mendelson Director Open-market purchase +1,000 $6.50 $6,500
Jan 11, 2024 Daniel Newman Mendelson Director Open-market purchase +2,000 $6.27 $12,540
Jan 10, 2024 Daniel Newman Mendelson Director Open-market purchase +2,944 $6.31 $18,577
Jan 9, 2024 Daniel Newman Mendelson Director Open-market purchase +3,000 $6.25 $18,750
Jan 8, 2024 Daniel Newman Mendelson Director Open-market purchase +1,000 $6.15 $6,150
Jan 5, 2024 Daniel Newman Mendelson Director Open-market purchase +2,000 $6.09 $12,180
Jan 4, 2024 Daniel Newman Mendelson Director Open-market purchase +3,000 $6.12 $18,360
Jan 3, 2024 Daniel Newman Mendelson Director Open-market purchase +500 $5.83 $2,915
Dec 21, 2023 Daniel Newman Mendelson Director Open-market purchase +2,500 $4.92 $12,300
Dec 20, 2023 Daniel Newman Mendelson Director Open-market purchase +2,100 $4.82 $10,122

Organizations in the same sector, closest in location and size first.

Questions about Champions Oncology Inc.

Who is the CEO of Champions Oncology Inc.?

Robert Lawrence Brainin has been Champions Oncology Inc.'s CEO since June 2021.

How many directors are on Champions Oncology Inc.'s board?

Champions Oncology Inc.'s board has 7 directors: Daniel Newman Mendelson, David Sidransky, Joel Ackerman, Philip P. Breitfeld, Robert Lawrence Brainin, Ronnie Morris and Scott R. Tobin.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="champions-oncology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.